Table 3.
Effect of baseline glomerular filtration rate on 24-month visual and anatomic outcomes
| Characteristics | GFR ≤ 60 ml/min/1.73 m2 (n = 57) | GFR > 60 ml/min/1.73 m2 (n = 85) | p-value |
|---|---|---|---|
| Baseline characteristics | |||
| HbA1c, %, mean (SD) | 8.1 (1.8) | 8 (1.9) | 0.626 |
| GFR, ml/min/1.73 m2, mean (SD) | 36.2 (14) | 85.6 (12.4) | < 0.001* |
| Treatment-naïve, n (%) | 20 (35%) | 36 (42%) | 0.488 |
| Sex, % female | 35.1% | 36.5% | 1.000 |
| Diabetes duration, years, mean (SD) | 20.9 (13.4) | 15.4 (9.5) | 0.015* |
| Age, years, mean (SD) | 67.4 (12.1) | 63.4 (9.8) | 0.039* |
| VA, letters, mean (SD) | 51.4 (23) | 57.2 (20) | 0.124 |
| CST, µm, mean (SD) | 401.9 (134.1) | 460.8 (133.2) | 0.014* |
| DME activity, n (%) | |||
| - Centre involving CSME | 24 (42%) | 24 (28%) | 0.108 |
| - Non-centre involving CSME | 2 (4%) | 3 (4%) | |
| - No CSME | 4 (7%) | 2 (2%) | |
| - Unknown | 27 (47%) | 56 (66%) | |
| Outcomes at 24 months | |||
| ∆VA from baseline, mean (95% CI) | 9.3 (4.5, 14.1) | 7.8 (4, 11.7) | 0.638 |
| Adjusted ∆VA from baseline, mean (95% CI) | 6.4 (2.4, 10.4) | 6.9 (3.7, 10.0) | 0.852b |
| Final VA, letters, mean (SD) | 60.7 (20.8) | 65.1 (18) | 0.201 |
| Gain ≥ 10 letters, n (%) | 24 (42%) | 39 (46%) | 0.786 |
| Gain ≥ 15 letters, n (%) | 17 (30%) | 22 (26%) | 0.772 |
| ∆CST from baseline, mean (SD) | – 94.8 (– 128, – 61.5) | – 96.8 (– 124.7, – 68.8) | 0.927 |
| Adjusted ∆CST from baseline, mean (SD) | – 115.0 (– 144.0, – 85.2) | – 85.0 (– 109.0, – 61.3) | 0.130b |
| Final CST, µm, mean (SD) | 307.1 (112.7) | 364 (124.2) | 0.008* |
| CST ≤ 250 µm, n (%) | 23 (43%) | 14 (17%) | 0.003* |
| Injections, median (Q1, Q3)a | 7 (3, 12) | 10 (7, 13) | 0.042*b |
| Visits, median (Q1, Q3)a | 19 (18, 22) | 22 (16, 26) | 0.500b |
| Non-persistent DME rate, n (%) | 28 (49%) | 24 (28%) | 0.010* |
*Significant difference at p < 0.05
aData only for patients completing 24 months of therapy
ap-values and adjusted estimates were adjusted using linear regression, Poisson regression, or Cox proportional-hazards models for baseline VA, age, and CST; pre-treatment status; and practice